Kala Bio (KALA) Research & Development (2016 - 2026)
Kala Bio (KALA) posted Research & Development of $61000.0 for Q1 2026, down 83.33% sequentially from $366000.0 in Q4 2025, and down 98.99% YoY from $6.1 million in Q1 2025.
Kala Bio (KALA) Research & Development (2016 - 2026) Analysis & Trends
Kala Bio has reported Research & Development for 11 years, with the latest figure at $61000.0 in Q1 2026.
- Quarterly Research & Development fell 98.99% year-over-year to $61000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.8 million (down 41.34% YoY) and the FY2025 annual result came in at $18.8 million, down 15.0% from the prior year.
- Research & Development retreated to $61000.0 in Q1 2026 per KALA's latest filing, from $366000.0 in the prior quarter.
- Over five years, Research & Development peaked at $6.4 million in Q1 2024 and troughed at $61000.0 in Q1 2026.
- A 5-year average of $4.5 million and a median of $5.2 million in 2024 frame the typical range for Research & Development.
- The sharpest annual moves came in 2022 and 2026: Research & Development jumped 87.12% in 2022, then tumbled 98.99% in 2026.
- Over 5 years, Research & Development stood at $3.3 million in 2022, then surged by 41.98% to $4.7 million in 2023, then increased by 11.45% to $5.3 million in 2024, then sank by 93.04% to $366000.0 in 2025, then plunged by 83.33% to $61000.0 in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $61000.0, $366000.0, and $6.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Kala Bio | 9.87 Mn | 9.87 Mn | - | 61,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 61,000.00 |
| Dec 31, 2025 | 366,000.00 |
| Sep 30, 2025 | 6.13 Mn |
| Jun 30, 2025 | 6.23 Mn |
| Mar 31, 2025 | 6.06 Mn |
| Dec 31, 2024 | 5.26 Mn |
| Sep 30, 2024 | 5.17 Mn |
| Jun 30, 2024 | 5.32 Mn |
| Mar 31, 2024 | 6.35 Mn |
| Dec 31, 2023 | 4.72 Mn |
| Sep 30, 2023 | 5.55 Mn |
| Jun 30, 2023 | 4.28 Mn |
| Mar 31, 2023 | 4.04 Mn |
| Dec 31, 2022 | 3.32 Mn |
| Sep 30, 2022 | 5.39 Mn |
| Jun 30, 2022 | 4.47 Mn |
| Mar 31, 2022 | 4.47 Mn |
| Dec 31, 2021 | 2.41 Mn |
| Sep 30, 2021 | 2.88 Mn |
| Jun 30, 2021 | 3.09 Mn |